EUVIMEDEUVIMED entdecken
Crossref

Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model

Marie-Gabrielle Braun iD, Avi Ashkenazi, Ramsay E Beveridge, Georgette Castanedo, Heidi Ackerly Wallweber, Maureen H Beresini, Kevin R Clark, Tom De Bruyn iD, Liqiang Fu, Paul Gibbons, Fan Jiang, Susan Kaufman und 12 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.3c02425 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Marie-Gabrielle Braun und 23 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States. Hauptthemen laut MEDLINE: Multiple Myeloma, Protein Serine-Threonine Kinases, Endoribonucleases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The lack of selective and safe in vivo IRE1α tool molecules has limited the evaluation of IRE1α as a viable target to treat multiple myeloma. Focus on improving the physicochemical properties of a literature compound by decreasing lipophilicity, molecular weight, and basicity allowed the discovery of a novel series with a favorable in vitro safety profile and good oral exposure. These efforts culminated in the identification of a potent and selective in vivo tool compound, G-5758, that was well tolerated following multiday oral administration of doses up to 500 mg/kg. G-5758 demonstrated comparable pharmacodynamic effects to induced IRE1 knockdown as measured by XBP1s levels in a multiple myeloma model (KMS-11).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaProtein Serine-Threonine KinasesEndoribonucleasesHumansAdministration, OralAnimalsDrug DiscoveryMiceCell Line, TumorStructure-Activity RelationshipAntineoplastic AgentsRatsProtein Kinase InhibitorsGene Knockdown TechniquesX-Box Binding Protein 1

Substanzen

Protein Serine-Threonine KinasesERN1 protein, humanEndoribonucleasesAntineoplastic AgentsProtein Kinase InhibitorsX-Box Binding Protein 1

Autor:innen und Institutionen

  • Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
  • Paraza Pharma Inc., 2525 Ave. Marie-Curie, Montreal, QC, Canada H4S 2E1.
  • WuXi AppTec Co., Ltd., Shanghai 200131, P. R. China.
  • VIVA Biotech, No. 735, Ziping Road, Pudong New Area, Shanghai 201321, China.

ORCID-Profile: Marie-Gabrielle Braun, Tom De Bruyn, Jacob B Schwarz, Joachim Rudolph

Zitieren

APA

Braun, M. G., Ashkenazi, A., Beveridge, R. E., Castanedo, G., Wallweber, H. A., Beresini, M. H., Clark, K. R., De Bruyn, T., Fu, L., Gibbons, P., Jiang, F., Kaufman, S., Kan, D., Kiefer, J. R., Leclerc, J. P., Lemire, A., Ly, C., Segal, E., Sims, J., …, & Rudolph, J. (2024). Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02425

Vancouver

Braun MG, Ashkenazi A, Beveridge RE, Castanedo G, Wallweber HA, Beresini MH, et al. Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02425

BibTeX
@article{Braun2024,
  author = {Braun, Marie-Gabrielle and Ashkenazi, Avi and Beveridge, Ramsay E and Castanedo, Georgette and Wallweber, Heidi Ackerly and Beresini, Maureen H and Clark, Kevin R and De Bruyn, Tom and Fu, Liqiang and Gibbons, Paul and Jiang, Fan and Kaufman, Susan and Kan, David and Kiefer, James R and Leclerc, Jean-Philippe and Lemire, Alexandre and Ly, Cuong and Segal, Ehud and Sims, Jessica and Wang, Weiru and Wei, Wentao and Zhao, Liang and Schwarz, Jacob B and Rudolph, Joachim},
  title = {Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.3c02425}
}
Kostenlos starten →